Literature DB >> 17902293

An unusual cause of cerebral venous sinus thrombosis: prothrombin G20210A gene mutation.

Mateo Porres-Aguilar1, Jaime H Square, Raul Storey, Simon Rodriguez-Dunn, Mohamed S Mohamed-Aly.   

Abstract

Cerebral venous sinus thrombosis represents less than 1% of all strokes, being an uncommon entity with a wide spectrum of clinical scenarios. We present a 45-year-old Hispanic female with a history of long-term oral contraceptive use who was diagnosed with cerebral venous sinus thrombosis due to a heterozygous carrier mutation in the prothrombin G20210A gene. The patient was successfully managed with intravenous heparin with favorable clinical results without adverse effects. The prevalence of inherited primary thrombophilia increases with additional risk factors such as the use of oral contraceptives that can trigger or prothrombotic events in any vascular bed. An increased prevalence in the prothrombin G20210 gene mutation has been demonstrated in the Mexican-Mestizo population. Controversy exists regarding therapy of cerebral venous sinus thrombosis; according to experts, heparin remains the cornerstone of therapy with acceptable outcomes. More clinical trials are required to evaluate long-term outcomes in this subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902293     DOI: 10.1097/SMJ.0b013e3181462a5f

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Mutation in the Prothrombin Gene G20210A as a Cause of Cerebral Venous Thrombosis.

Authors:  Jorge A Arroyave; Jairo Quiñones
Journal:  Case Rep Med       Date:  2012-05-08

2.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study.

Authors:  Mohammad Saadatnia; Mansour Salehi; Ahmad Movahedian; Seyed Ziaeddin Samsam Shariat; Mehri Salari; Marzieh Tajmirriahi; Elham Asadimobarakeh; Rasoul Salehi; Gilda Amini; Homa Ebrahimi; Ehsan Kheradmand
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.